Seems like there has been a mad dash into almost anything biotech lately.
Today OMER had its move, +65% as of 2pm.
According to the company, OMS721 has completed its mid-dose testing and is nearing the end of the high-dose phase of the treatment's mid-stage trial as well. What sent shares soaring, though, was the announcement that two patients in the mid-dose group with plasma therapy-resistant aHUS demonstrated clinically meaningful improvements in several areas, such as mean platelet count, mean schistocyte count, mean haptoglobin, and mean levels of LDH. The first patient to complete the high dose regimen of OMS721 showed a marked improvement in several biomarkers as well.
Submitted August 18, 2015 at 02:05PM by StockJock-e http://ift.tt/1JoWAAm
No comments:
Post a Comment